Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Improving Drug Safety – Without FDA: HHS Adverse Event Report Focuses On Other Agencies

This article was originally published in RPM Report

Executive Summary

HHS is declaring a priority of reducing the burden of adverse events associated with three large classes of drugs: opioids, antidiabetics, and anticoagulants. And, at least in its draft action plan, FDA is not the central actor.

You may also be interested in...

HHS’ Adverse Drug Event Action Plan Calls For New Treatment Guidelines

Draft recommends research and initiatives that could lead to changes in drug prescribing practices to reduce the likelihood of adverse drug events – and may even include more prescribing if adverse drug events can be mitigated.

Selling Sentinel: FDA Highlights Vision For Broader Role For Data Network At Brookings

FDA’s Janet Woodcock used her time at a conference on biomedical innovation to highlight ways to use FDA’s Sentinel network more broadly to standardize, and hopefully streamline comparative effectiveness research.

CMS and Opioids: The Role for Non-Drug Reimbursements

The Centers for Medicare and Medicaid Services proposed Part D rules to give plans some responsibility for monitoring opioid abuse. But providers at a Senate Finance Hearing think CMS reimbursements beyond drugs can have a role in screening abuse – and in treating pain to begin with.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts